Data as of 2:05pm ET
| -0.06 / -2.31%|
The 2 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 6.00, with a high estimate of 7.00 and a low estimate of 5.00. The median estimate represents a +136.22% increase from the last price of 2.54.
The current consensus among 2 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.